These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37290280)

  • 21. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse.
    Taylor TN; Potgieter D; Anwar S; Senior SL; Janezic S; Threlfell S; Ryan B; Parkkinen L; Deltheil T; Cioroch M; Livieratos A; Oliver PL; Jennings KA; Davies KE; Ansorge O; Bannerman DM; Cragg SJ; Wade-Martins R
    Neurobiol Dis; 2014 Feb; 62():193-207. PubMed ID: 24121116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity.
    Ysselstein D; Joshi M; Mishra V; Griggs AM; Asiago JM; McCabe GP; Stanciu LA; Post CB; Rochet JC
    Neurobiol Dis; 2015 Jul; 79():150-63. PubMed ID: 25931201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha-synuclein in Parkinson's disease: a villain or tragic hero? A critical view of the formation of α-synuclein aggregates induced by dopamine metabolites and viral infection.
    Carmo-Gonçalves P; Coelho-Cerqueira E; de Araujo Lima V; Follmer C
    Expert Rev Neurother; 2023 Apr; 23(4):321-330. PubMed ID: 37016954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein.
    Subramaniam SR; Vergnes L; Franich NR; Reue K; Chesselet MF
    Neurobiol Dis; 2014 Oct; 70():204-13. PubMed ID: 25016198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.
    Zondler L; Miller-Fleming L; Repici M; Gonçalves S; Tenreiro S; Rosado-Ramos R; Betzer C; Straatman KR; Jensen PH; Giorgini F; Outeiro TF
    Cell Death Dis; 2014 Jul; 5(7):e1350. PubMed ID: 25058424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
    Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
    Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nurr1 repression mediates cardinal features of Parkinson's disease in α-synuclein transgenic mice.
    Argyrofthalmidou M; Spathis AD; Maniati M; Poula A; Katsianou MA; Sotiriou E; Manousaki M; Perier C; Papapanagiotou I; Papadopoulou-Daifoti Z; Pitychoutis PM; Alexakos P; Vila M; Stefanis L; Vassilatis DK
    Hum Mol Genet; 2021 Jul; 30(16):1469-1483. PubMed ID: 33902111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons.
    Ganjam GK; Bolte K; Matschke LA; Neitemeier S; Dolga AM; Höllerhage M; Höglinger GU; Adamczyk A; Decher N; Oertel WH; Culmsee C
    Cell Death Dis; 2019 Nov; 10(11):865. PubMed ID: 31727879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein.
    Landeck N; Strathearn KE; Ysselstein D; Buck K; Dutta S; Banerjee S; Lv Z; Hulleman JD; Hindupur J; Lin LK; Padalkar S; Stanciu LA; Lyubchenko YL; Kirik D; Rochet JC
    Mol Neurodegener; 2020 Sep; 15(1):49. PubMed ID: 32900375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional Interaction Between α-Synuclein and Nurr1 in Dopaminergic Neurons.
    Argyrofthalmidou M; Polissidis A; Karaliota S; Papapanagiotou I; Sotiriou E; Manousaki M; Papadopoulou-Daifoti Z; Spillantini MG; Stefanis L; Vassilatis DK
    Neuroscience; 2022 Dec; 506():114-126. PubMed ID: 36270413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damage.
    Paiva I; Pinho R; Pavlou MA; Hennion M; Wales P; Schütz AL; Rajput A; Szego ÉM; Kerimoglu C; Gerhardt E; Rego AC; Fischer A; Bonn S; Outeiro TF
    Hum Mol Genet; 2017 Jun; 26(12):2231-2246. PubMed ID: 28369321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease.
    Sakai R; Suzuki M; Ueyama M; Takeuchi T; Minakawa EN; Hayakawa H; Baba K; Mochizuki H; Nagai Y
    PLoS One; 2019; 14(6):e0218261. PubMed ID: 31242217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy.
    Moors TE; Maat CA; Niedieker D; Mona D; Petersen D; Timmermans-Huisman E; Kole J; El-Mashtoly SF; Spycher L; Zago W; Barbour R; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Geurts JJG; Gerwert K; Britschgi M; van de Berg WDJ
    Acta Neuropathol; 2021 Sep; 142(3):423-448. PubMed ID: 34115198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.
    Cole TA; Zhao H; Collier TJ; Sandoval I; Sortwell CE; Steece-Collier K; Daley BF; Booms A; Lipton J; Welch M; Berman M; Jandreski L; Graham D; Weihofen A; Celano S; Schulz E; Cole-Strauss A; Luna E; Quach D; Mohan A; Bennett CF; Swayze EE; Kordasiewicz HB; Luk KC; Paumier KL
    JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33682798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF.
    Vidal-Martínez G; Vargas-Medrano J; Gil-Tommee C; Medina D; Garza NT; Yang B; Segura-Ulate I; Dominguez SJ; Perez RG
    J Biol Chem; 2016 Sep; 291(39):20811-21. PubMed ID: 27528608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.
    Xilouri M; Vogiatzi T; Vekrellis K; Park D; Stefanis L
    PLoS One; 2009; 4(5):e5515. PubMed ID: 19436756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of alpha-synuclein in the development of the dopaminergic neurons in the substantia nigra and ventral tegmental area.
    Tarasova TV; Lytkina OA; Roman AY; Bachurin SO; Ustyugov AA
    Dokl Biol Sci; 2016; 466():5-7. PubMed ID: 27021360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.